Literature DB >> 28444730

Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.

Deborah Assouan1, Delphine Lebon1, Amandine Charbonnier1, Bruno Royer1, Jean-Pierre Marolleau1, Berengere Gruson1.   

Abstract

Entities:  

Keywords:  corticosteroids; graft-versus-host disease; hematopoietic stem cell transplantation; malignant haematology; ruxolitinib

Mesh：

Substances：

Year:  2017        PMID： 28444730     DOI： 10.1111/bjh.14679

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113

2.  Ruxolitinib for Therapy of Graft-versus-Host Disease.

Authors:  Thomas Neumann; Laila Schneidewind; Martin Weigel; Andrzej Plis; Rem Vaizian; Christian A Schmidt; William Krüger
Journal:  Biomed Res Int       Date:  2019-03-06       Impact factor: 3.411

3.  Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge.

Authors:  Jerry Yung-Lun Chin; Jiayi Gong; Edward Gane
Journal:  ACG Case Rep J       Date:  2020-12-21

4.  Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.

Authors:  Martina Kaurinovic; Konstantina Delli; Ana-Mae E Jonk; Anouschka Biswana; Carin L E Hazenberg; Goda Choi; Marco R de Groot; Linde M Morsink; Arjan Vissink; Mar Bellido
Journal:  Clin Oral Investig       Date:  2022-02-16       Impact factor: 3.606

5.  Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.

Authors:  Meng-Yun Zhang; Peng Zhao; Yan Zhang; Ji-Shi Wang
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.